In which country was the patent for imatinib originally developed?

Imatinib/Glivec, trade name Glivec (Glivec), was originally developed by the Swiss pharmaceutical company Novartis. In 2001, Novartis launched this drug and successfully obtained approval from many countries around the world, becoming a standard treatment drug for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

The development and launch of imatinib not only represents an important breakthrough in targeted therapy drugs, but also has a profound impact on the global cancer treatment field. Unlike traditional chemotherapy drugs, imatinib precisely targets the BCR-ABL tyrosine kinase in tumor cells, inhibits its abnormal activation, reduces damage to healthy cells, significantly improves patients' quality of life, and greatly reduces the occurrence of side effects.

The successful launch of imatinib marks the arrival of the era of molecular targeted therapy and provides new treatment options for many refractory cancers. After years of clinical application, the efficacy and safety of imatinib have been widely recognized by the global medical community, and it has become the cornerstone drug for the treatment of chronic myelogenous leukemia.

Novartis has promoted the global application of imatinib through continuous R&D and innovation and made important contributions to the advancement of cancer treatment. At present, imatinib has become an important therapeutic drug worldwide, and patients in many countries and regions have benefited from its therapeutic effects.

Therefore, imatinib was originally developed and patented by Novartis in Switzerland. The emergence of this drug not only changed the treatment model of chronic myelogenous leukemia and gastrointestinal stromal tumors, but also laid the foundation for the development of targeted therapeutic drugs.

Reference materials:https://www.gleevec.com/